Jonsson Comprehensive Cancer Center

INKmune Trial for Metastatic Prostate Cancer Expands to VA Medical Center

4 months ago

• INmune Bio's CaRe PC trial, evaluating INKmune in metastatic castration-resistant prostate cancer (mCRPC), has expanded to the West Los Angeles VA Medical Center. • The first patient at the VA Medical Center has been dosed with the 'medium' dose of INKmune, marking the official expansion of the trial to veterans with mCRPC. • The Phase 1/2 trial assesses the safety and anti-tumor activity of INKmune across three dose levels, with a six-month follow-up to measure immune and anti-cancer responses. • Initial Phase 1 data showed changes in NK cell phenotype and function in all patients, with one patient experiencing a transient decrease in prostate-specific antigen (PSA).

Radiopharmaceutical Antibody-Drug Conjugates (rADCs) Emerge as Promising Cancer Therapies

9 months ago

• rADCs are designed to deliver radiation directly to cancer cells, minimizing side effects compared to traditional radiation therapy. • Several companies are developing rADCs with various radioisotopes and antibodies, targeting cancers like prostate, breast, and lung cancer. • Clinical trials are underway to assess the efficacy and safety of rADCs, showing promising results in reducing tumor markers like PSA. • Challenges remain in supply chain logistics, dosimetry, and optimizing drug delivery to target tissues for effective cancer treatment.

PSMA PET-CT Improves Prostate Cancer Metastasis Detection

5 years ago

• PSMA PET-CT imaging proves more accurate than standard CT and bone scans in detecting prostate cancer metastasis, with 92% accuracy versus 65%. • The use of PSMA PET-CT led to a change in treatment plans for 28% of patients, compared to 15% with standard imaging, optimizing patient care. • PSMA PET-CT reduces inconclusive results (7% versus 23%), minimizing the need for additional scans and biopsies, streamlining diagnosis. • FDA approved Gallium (Ga) 68 PSMA-11 for PET imaging in prostate cancer, enhancing detection of spread and recurrence based on PSA levels.